The United States government and Pfizer reached an agreement to delay the U.S. regulatory decision on the company’s COVID-19 vaccine for children as young as 6 months old, Pfizer’s CEO said on March 13. “We all agreed it’s better if we wait for the three doses to come out,” CEO Albert Bourla said on CBS’ “Face the Nation.” Pfizer and its partner BioNTech have been testing their vaccine on children aged 6 months to 4 years but announced in late 2021 that they were expanding the clinical trial to three doses because the two-dose primary regimen didn’t trigger a sufficient immune response in some of the kids. Instead of waiting for the expanded trial to be completed, the U.S. Food and Drug Administration (FDA) soon after asked Pfizer for data on the vaccine. Because of the spike in COVID-19 cases and hospitalizations from the Omicron virus variant, regulators were considering …